secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056260
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Q1 net loss $21.7M; cash $195.1M after $95M PIPE; pipeline milestones on track
--------------------------------------------------------------------------------

- Q1 2024 net loss $21.7M ($0.77/share) vs $18.7M ($11.58/share) in Q1 2023.
- Cash and equivalents $195.1M at March 31, 2024, after $95M PIPE; runway into 2027.
- LX2006 (FA cardiomyopathy) granted FDA Fast Track; interim readout mid-2024.
- LX2020 (PKP2-ACM) Phase 1/2 trial recruiting; Cohort 1 data update expected 2H 2024.
- LX1001 (APOE4 Alzheimer's) all-cohort interim data expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024056260/0000950170-24-056260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024056260/lxeo-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer